XML 14 R48.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS COMBINATIONS (Details) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended
Feb. 28, 2012
Mar. 31, 2012
Mar. 31, 2013
Mar. 31, 2012
Acquisition-related costs: [Abstract]        
Acquisition-related costs     $ 519,000 $ 8,460,000
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Revenue     73,854,000 51,717,000
Net income     10,842,000 3,108,000
Kilitch Drugs (India) Limited [Member]
       
Business Acquisition [Line Items]        
Business Acquisition, Effective Date of Acquisition Feb. 28, 2012      
Business Acquisition, Date of Acquisition Agreement Oct. 05, 2011      
Total consideration paid 60,100,000      
Base consideration paid 51,200,000      
Reimbursement for capital expenditure 4,000,000      
Contingent consideration earned 7,800,000   500,000  
Acquisition-related costs: [Abstract]        
Acquisition-related costs     500,000 8,800,000
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Revenue   900,000 5,100,000  
Pre-tax loss   8,300,000 1,200,000  
Kilitch Drugs (India) Limited [Member] | Minimum [Member]
       
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Acquired finite-lived intangible assets useful life     4 years  
Kilitch Drugs (India) Limited [Member] | Maximum [Member]
       
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Acquired finite-lived intangible assets useful life     5 years  
Kilitch Drugs (India) Limited [Member] | Initial Fair Valuation [Member]
       
Consideration [Abstract]        
Cash paid 55,224,000      
Less working capital shortfall refunded by sellers (890,000)      
Total Purchase Price 54,334,000      
Acquisition-related costs: [Abstract]        
Stamp duties paid for transfer of land and buildings 1,583,000      
Acquisition-related compensation expense 6,741,000      
Due diligence, legal, travel and other acquisition-related costs 557,000      
Acquisition-related costs 8,881,000      
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Accounts receivable 2,130,000      
Inventory 1,799,000      
Land 3,714,000      
Buildings, plant and equipment 8,474,000      
Construction in progress 14,231,000      
Goodwill, deductible 21,609,000      
Other intangible assets, deductible 5,806,000      
Other assets 38,000      
Assumed liabilities (2,099,000)      
Deferred tax liabilities (1,368,000)      
Business combination, recognized amounts of identifiable assets acquired and liabilities assumed, net 54,334,000      
Kilitch Drugs (India) Limited [Member] | Change in Estimate [Member]
       
Consideration [Abstract]        
Less working capital shortfall refunded by sellers (138,000)      
Total Purchase Price (138,000)      
Acquisition-related costs: [Abstract]        
Acquisition-related compensation expense 1,030,000      
Due diligence, legal, travel and other acquisition-related costs 119,000      
Acquisition-related costs 1,149,000      
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Land (1,131,000)      
Goodwill, deductible 1,004,000      
Other intangible assets, deductible 102,000      
Assumed liabilities (779,000)      
Deferred tax liabilities 666,000      
Business combination, recognized amounts of identifiable assets acquired and liabilities assumed, net (138,000)      
Kilitch Drugs (India) Limited [Member] | Adjusted Fair Valuation [Member]
       
Consideration [Abstract]        
Cash paid 55,224,000      
Less working capital shortfall refunded by sellers (1,028,000)      
Total Purchase Price 54,196,000      
Acquisition-related costs: [Abstract]        
Stamp duties paid for transfer of land and buildings 1,583,000      
Acquisition-related compensation expense 7,771,000      
Due diligence, legal, travel and other acquisition-related costs 676,000      
Acquisition-related costs 10,030,000      
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Accounts receivable 2,130,000      
Inventory 1,799,000      
Land 2,583,000      
Buildings, plant and equipment 8,474,000      
Construction in progress 14,231,000      
Goodwill, deductible 22,613,000      
Other intangible assets, deductible 5,908,000      
Other assets 38,000      
Assumed liabilities (2,878,000)      
Deferred tax liabilities (702,000)      
Business combination, recognized amounts of identifiable assets acquired and liabilities assumed, net 54,196,000      
Kilitch Drugs (India) Limited [Member] | Pro Forma [Member]
       
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract]        
Revenue       55,721,000
Net income       $ 1,572,000
Net income per diluted share (in dollars per share)       $ 0.01